Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Basal Ganglia Diseases » Parkinsonian Disorders » Parkinson Disease
Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Movement Disorders » Parkinsonian Disorders » Parkinson Disease
Diseases [C] » Nervous System Diseases [C10] » Neurodegenerative Diseases » Synucleinopathies » Parkinson Disease
Description
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) MeSH
Hierarchy View
Approved Indicated Drugs (29)
Phase 4 Indicated Drugs (43)
Phase 3 Indicated Drugs (48)
Phase 1 Indicated Drugs (87)
Other Experimental Indicated Drugs (51)
Organization Involved with Phase 4 Indications (131)
Adolphe Rothschild Ophtalmologic Foundation
Ankara Yildirim Beyazıt University
Autonomous University of Barcelona
Booth Gardner Parkinson's Care Center
Centre Hospitalier du Pays d'Aix
Centre Hospitalier Universitaire de Nīmes
Hoosier Cancer Research Network
Huazhong University of Science and Technology
International Parkinson Fonds Germany GmbH
I.R.C.C.S. Fondazione Santa Lucia
Kuhnil Pharmaceutical Co., Ltd.
Methodist Cancer Center, Houston, Texas
Michael J. Fox Foundation for Parkinson's Research
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
Oregon Health and Science University
Parkinson's Disease and Movement Disorder Center of Boca Raton
Parkinson's Disease Foundation
Swedish Parkinson's Disease Foundation
Swedish Society for Medical Research
Technical University of Dresden
Organization Involved with Phase 3 Indications (154)
All India Institute of Medical Sciences
Apollo Hospitals, Chennai, India
Autonomous University of Madrid
Baby Memorial Hospital, Calicut
Beijing Bionovo Medicine Development Co., Ltd.
Brain and Mind Institute, Nagpur
Britannia Pharmaceuticals Ltd.
Canadian Institutes of Health Research (CIHR)
Chhatrapati Sahuji Maharaj Medical University
Chongqing Fortune Pharmaceutical Co., Ltd.
Cura Villa Margherita, Vicenza, Italy
D'Annunzio University of Chieti–Pescara
Deutsche Parkinson Vereinigung
Hospital Salvador-Neurologia, Santiago, Chile
Institute of Human Behaviour and Allied Sciences, Dilshad Garden Delhi
Instituto Mexicano del Seguro Social
Jaslok Hospital and Research Centre, Mumbai, India
J.S.S. Medical College Hospital
Kamakshi Memorial Hospital, Chennai
Kerala Institute of Medical Sciences, Trivandrum
Kovai Medical Centre and Hospital, Coimbatore
Lancashire Teaching Hospitals NHS Foundation Trust
Liga Chilena Contra el Mal De Parkinson, Santiago, Chile
Mallikatta Neuro and Research Centre, Mangalore
Mazandaran University of Medical Sciences
Medical University of South Carolina
Movement Disorder Clinic - Deer Lodge Centre
M.S. Ramaiah Medical College, Bangalore, India
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Mental Health and Neuro Sciences, India
National University of Singapore
Nizam's Institute of Medical Sciences, Hyderabad, India
Office of Dietary Supplements (ODS)
Ospedale della Misericordia - Grosseto
Ospedale di Viareggio, Viareggio
Osp. S. Giovanni Battista, Roma, Italy
Owaisi Hospital & Research Centre
P.D. Hinduja Hospital and Medical Research Centre, Mumbai
People's Liberation Army of China
Pharmaceutical Research Associates, Inc. (PRA)
Postgraduate Institute of Medical Education and Research
Rajiv Gandhi University of Health Sciences
Roby General Hospital, Kolkata
Sree Chitra Tirual Institute for Sciences and Technology, Kerela
Sri Aurbindo Seva Kendra, Kolkata
T.N.M.C and B.Y.L Nair Hospital, Mumbai
Universidad Complutense de Madrid
University Hospital Plymouth NHS Trust
University of British Columbia
University of California, Los Angeles
University of Medicine and Dentistry of New Jersey
University of Medicine and Pharmacy Cluj-Napoca, Romania
University of Naples Frederico II
University of Rome Tor Vergata
Vidyasagar Institute of Mental Health and Neurosciences, New Delhi
Organization Involved with Phase 2 Indications (210)
1st Hospital of Social Security Services
Alanya Alaaddin Keykubat University
Alexandra Marine and General Hospital
Amarantus BioScience Holdings, Inc.
Antipodean Pharmaceuticals, Inc.
A.O. Ospedale Card G. Panico di Tricase
Auckland District Health Board
Azienda Ospedaliera Cardinale G. Panico
Belarusian Medical Academy of Post-Graduate Education
Center for Neurology, Stockholm
Centro Inmunologia Molecular (CIM)
Centro Nacional Producción Animales de Laboratorio (CENPALAB)
Chinese Academy of Medical Sciences
Colorado Department of Public Health and Environment
Custom Pharmaceuticals Limited
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Fondazione Grigioni per il Morbo di Parkinson
Genervon Biopharmaceuticals, LLC
Gene Therapy Research Institution,Co.,Ltd.
German Parkinson Study Group (GPS)
Hospital of Mental Diseases of Tripolis
Institute for Neurodegenerative Disorders
Integrative Research Laboratories AB
International Center for Neurological Restoration, Cuba
Joseph and Rosalyn Newman Foundation
JP Moulton Charitable Foundation
KTH Royal Institute of Technology
National Cheng Kung University
NeuroHealing Pharmaceuticals Inc.
Oriental Neurosurgery Evidence-Based-Study Team
Paracelsus Elena Klinik Kassel
Parkinson's Disease Society of the United Kingdom
Philipps University of Marburg
PRO.MED.CS Praha a.s - Czech Republic
Queensland University of Technology
Shahid Beheshti University of Medical Sciences
Statistecol Consultants Limited
St Josephs Hospital and Medical Center
The University of Texas, Dallas
University of Alabama, Birmingham
University of California, San Diego
University of Colorado, Denver
University of Electronic Science and Technology of China
University of Illinois at Chicago
University of Texas at Houston
Washington University in St. Louis
Organization Involved with Phase 1 Indications (80)
Allife Medical Science and Technology Co., Ltd.
Beijing Bozhiyin T&S Co., Ltd.
Clinical Research Services Turku
Feinstein Institute for Medical Research
Hammersmith Medicines Research
Hebei Chemical & Pharmaceutical College
Hebei Newtherapy BIo-Pharma technology Co., Ltd.
Hong Kong WD Pharmaceutical Co., Limited
Kelsey Seybold Research Foundation
Korea Health Industry Development Institute
Medical Research Foundation, Oregon
National Center for Advancing Translational Science (NCATS)
National Center for Research Resources (NCRR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Deafness and Other Communication Disorders (NIDCD)
Nebraska Neuroscience Alliance
New York Institute of Technology
Organization Involved with Other Experimental Indications (37)
Association Institut de Myologie
Bioengineering Center, Grape King Bio
Colorado Springs Neurological Associates
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
